%0 Journal Article %A George J Milne %A Julian Carrivick %A David Whyatt %T Non-pharmaceutical interventions and vaccinating school children required to contain SARS-CoV-2 Delta variant outbreaks in Australia: a modelling analysis %D 2021 %R 10.1101/2021.10.03.21264492 %J medRxiv %P 2021.10.03.21264492 %X Background In countries with high COVID-19 vaccination rates the SARS-CoV-2 Delta variant has resulted in rapidly increasing case numbers. This study evaluated the use of non-pharmaceutical interventions (NPIs) coupled with alternative COVID-19 vaccination strategies to determine feasible Delta mitigation strategies for Australia. We aimed to understanding the interplay between high vaccine coverage levels and NPI physical distancing activation, and to establish the benefit of adding children and adolescents to the vaccination program. Border closure has limited SARS-CoV-2 transmission in Australia, however slow vaccination uptake resulted in Delta outbreaks in the two largest cities, and may continue once international travel resumes.Methods An agent-based model was used to evaluate the potential reduction in the COVID-19 health burden resulting from alternative vaccination strategies. We assumed immunity was derived from vaccination with the BNT162b2 Pfizer BioNTech vaccine. Two age-specific vaccination strategies were evaluated, age 5 and above, and 12 and above, and the health burden determined under alternative coverages, with/without activation of NPIs. Age-specific infections generated by the model, together with recent UK data, permitted reductions in the health burden to be quantified.Results Cases, hospitalisations and deaths are shown to reduce by: i) increasing coverage to include children aged 5 to 11 years, ii) activating moderate NPI measures, and/or iii) increasing coverage levels above 80%. At 80% coverage, vaccinating ages 12 plus without NPIs is predicted to give 1,162 hospitalisations; adding ages 5 and above gives 1,073 cases per million population. Activating moderate NPIs reduces hospitalisations to 705. Alternatively, increasing coverage to 90% reduces this to 684. Combining all three measures is shown to reduce cases to 398, hospitalisations to 2 and deaths to zero.Conclusions Delta variant outbreaks may be successfully managed by an achievable 80% vaccine coverage rate and moderate NPI measures, allowing schools and many workplaces to remain open. This prevents use of hard lockdown measures, and consequential economic and societal damage. Activating moderate NPIs is shown to give a similar reduction in health burden as increasing coverage of ages 12 and above to 90%. If 90% coverage cannot be achieved, including children and adolescents in the vaccination program coupled with moderate NPIs appears necessary to contain future COVID-19 Delta transmission.Funding The authors acknowledge funding support from the Department of Health, Western Australia (Future Health Research and Innovation Fund) and the Department of Health, Queensland, Australia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge funding support from the Department of Health, Western Australia (Future Health Research and Innovation Fund) and the Department of Health, Queensland, Australia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to is publicly available %U https://www.medrxiv.org/content/medrxiv/early/2021/10/04/2021.10.03.21264492.full.pdf